Ferring Pharmaceuticals Targeting Inflammatory Bowel Disease With Bacteriophage-based Therapy

Ferring Pharmaceuticals Targeting Inflammatory Bowel Disease With Bacteriophage-based Therapy
Ferring Pharmaceuticals recently initiated a new research and development collaboration with Intralytix to develop a bacteriophage-based therapy for Inflammatory Bowel Disease (IBD). InflammatoryBowel Disease (IBD) is characterized by chronic inflammation in the digestive tract (either in its entirety or focused on particular areas of the GI) and includes two major designated conditions, ulcerative colitis and Crohn's disease. The symptoms include severe diarrhea, pain, fatigue and weight loss, and it is estimated to affect 1 to 1.3 million people in the United States alone, according to Centers for Disease Control and Prevention (CDCP). The novel therapy being developed is based on bacteriophages, i.e., viruses that infect and replicate inside bacteria, leading to bacteria-death during the replication process. Recently, a specific strain of the bacteria Escherichia coli (AIEC) was linked to Crohn's disease, one of the phenotypic forms of IBD. As a result of this discovery, the team of researchers at Ferring Pharmaceuticals developed a project to understand the role of the AIEC strain in IBD (in a partnership with the University of Lille, University of Auvergne and DigestScience, which investigates digestive diseases). In a second phase of the study, the researchers worked together with Ferring at the Institute Pasteur, and Intralytix and developed different bacteriophages that specifically target the various AIEC bac
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *